Johnson & Johnson, like businesses in every sector, has had to draw on crisis management skills in response to Covid-19.

For pharma companies, staff have had to continue working on site throughout the pandemic as patients are relying on the production of healthcare products and medicines.

We spoke to Gary Hartnett, general manager of Johnson & Johnson’s Janssen Ireland pharma business, about how his team adopted “a very agile operational model” to continue manufacturing key products.

Johnson & Johnson employs more than 3,750 people in Ireland and looking after them has been a priority for Hartnett and his team. This extends beyond workplace changes and updates, he explained, as Covid-19 has “created an extra burden” for many that shouldn’t be overlooked.


Words by Lisa Ardill